Mid-December, many people are focused on activities and information related to the holidays. The news media are no exception, with very little attention paid to health care research, unless it has a holiday hook. As a result, news is slim about various advancements in understanding, treating and preventing disease. Nonetheless, Mayo Clinic Research and researchers are present, including in stories about new algorithms, esophageal cancer, adult ADHD, heart disease and more. As well as the ever-present, albeit perhaps not the traditional type of gifts one expects – advancements and increased understanding related to COVID-19. Read on to learn more.
NOTE: The next edition of Mayo Clinic Research in the news will be Thursday, 12/31 (New Year's Eve).
HIT Consultant, 12/15/2020
TripleBlind announced today it is collaborating with Mayo Clinic researchers who will use TripleBlind tools to validate interoperability of encrypted algorithms on encrypted data and the training of new algorithms on encrypted data. TripleBlind has created a rapid, efficient and cost effective data privacy focused solution based on breakthroughs in advanced mathematics, which will be used and validated by the Mayo team. No Mayo data will be accessed by TripleBlind. …
Technology Networks via AACR, 12/16/2020
Esophageal adenocarcinoma is occurring more frequently in adults under age 50, and these younger adults are more likely to be diagnosed at advanced stages, according to a study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.
Esophageal cancer is a relatively rare cancer, with 18,440 cases expected to be diagnosed in the United States this year, according to the Surveillance, Epidemiology, and End Results (SEER) database. While those cases account for only about 1 percent of U.S. cancer diagnoses, esophageal cancer has poor survival outcomes, with a five-year survival rate of only 19.9 percent.
“Patients who present with late-stage esophageal cancer typically have poorer outcomes than those with early-stage disease. As such, it is important to understand the epidemiology of esophageal cancer to target our screening strategies,” said the study’s corresponding author, Prasad G. Iyer, MD, MSc, professor of medicine in the Barrett’s Esophagus Unit, Division of Gastroenterology and Hepatology at the Mayo Clinic in Rochester, Minnesota. …
Healio Gastroenterology, 12/15/2020
The American College of Gastroenterology developed clinical guidelines for the treatment of irritable bowel syndrome.
“We believe that the information provided in this guideline will help guide both practitioners and researchers for years to come,” Brian E. Lacy, PhD, FACG, from the Mayo Clinic in Jacksonville, Florida, and colleagues said in recommendations published in the American Journal of Gastroenterology. “However, as this extensive project evolved, we recognized that there are still significant gaps in our knowledge. Future research is needed to better understand the role of the gut microbiome in patients with IBS and to understand the genesis of visceral pain.” …
My Plainview via AHA News, 12/17/2020
People with heart valve disease have a growing number of treatment options that could allow them to avoid surgery except in the most severe cases, according to new guidelines.
The recommendations, meant to advise health care providers and developed jointly by the American Heart Association and American College of Cardiology, call for the use of less invasive treatment for conditions that make it difficult for heart valves to open and close normally, disrupting heart blood flow.
… The new guidelines were written to help doctors keep up with a rapidly changing field, said guideline writing committee co-chair Dr. Rick A. Nishimura. "There is a knowledge explosion in medicine today, which can overwhelm the clinician," Nishimura said in a news release. He is the Judd and Mary Morris Leighton Professor of Cardiovascular Diseases at the Mayo Clinic in Rochester, Minnesota. "This is particularly true in the area of valvular heart disease, in which multiple investigational trials are being rapidly performed and released, so that it becomes extremely difficult for an individual clinician to keep up with optimal treatments for each specific patient."
… Although the hyperactivity symptoms of ADHD usually decrease with age, the inattention symptoms tend to continue or worsen over time. Impulsivity also often persists into adulthood, sometimes manifesting in risky behavior, Rooney says. For example, adults diagnosed with ADHD have a rate of car crashes 1.45 times higher than those without this diagnosis, according to an August 2020 study in the Journal of the American Academy of Child & Adolescent Psychiatry.
And, of course, the consequences of ADHD's core symptoms grow larger in adulthood, Hinshaw points out. As one needs to show more and more self-regulation in jobs and close relationships, ADHD-related symptoms can cause employment and interpersonal problems, as well as sleep issues, anxiety and depression.
That's why it's so important to recognize ADHD in adults and help them find treatment if necessary, says Jyoti Bhagia, a consultant in the department of psychiatry at the Mayo Clinic in Rochester, Minnesota. “It's treatable, and treatment helps people gain self-esteem, build better relationships and helps them be more effective on the job." …
Because no standard approaches exist for patients with EGFR-mutated non–small cell lung cancer (NSCLC) who progress on standard frontline osimertinib (Tagrisso), repeat genomic testing should be done to identify potential resistance mechanisms that can help guide the next step in the treatment journey, Rami Manochakian, MD.
“This is a very hot topic now. There are some potential rare, resistant mechanisms that could be a secondary actionable mutation such as MET amplification where you can potentially give patients another targeted therapy,” Manochakian explained. “For some other promising resistance mutations, you can enroll patients on trials, whether you have them at your institution or elsewhere. Definitely, for any patient of mine who progresses on osimertinib, I do recommend repeat genomic testing.”…
Tags: ADHD, antibodies, artificial intelligence, Barrett's esophagus, Brian Lacy, cancer, cardiovascular disease, clinical trials, COVID-19, data science, epidemiology, esophageal cancer, gastroenterology, health disparities, heart disease, hematology, IBS, irritable bowel syndrome, Jyoti Bhagia, lung cancer, News, Prasad Iyer, Rami Manochakian, Rick Nishimura, vaccines